Key Metrics of Alnylam Pharmaceuticals
Revenue₹8,575 Cr▲ 36.6% YoYFY 2022-23
EBITDA−₹6,122 Cr▼ 24.5% YoY
Net profit−₹9,350 Cr▼ 47.4% YoY
Net worth−₹1,308 Cr▼ 129.9% YoY
Market cap$23.3BALNY · $174.00
Competitors10identified
About Alnylam Pharmaceuticals
Sectors
Company details
- Website
- alnylam.com
- Founded
- 2004
- Listed
- Nasdaq: ALNY (since 2004)
Operational Areas of Alnylam Pharmaceuticals
Pharmaceuticals & Healthcare›Formulations & Contract Manufacturing
Company summary
Legal nameAlnylam Pharmaceuticals Inc.
TickerALNY
ExchangeNasdaq
CountryUnited States
SEC CIK0001178670
Listed since2004
IndustryBiotechnology: Pharmaceutical Preparations
SectorPharmaceuticals & Healthcare · Formulations & Contract Manufacturing
Websitehttp://www.alnylam.com
US market & SEC filings
ALNY · Nasdaq · SEC CIK 0001178670
Last price · 30 Oct 2026
$174.00
−25.13%
Market cap$23.3B
P/E—On FY 2023 diluted EPS
Volume11,802,860
SectorHealth CareBiotechnology: Pharmaceutical Preparations
Country · IPOUnited StatesListed 2004
ALNY share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricing
Premium
Financials, ratios and risk analysis
Revenue, EBITDA, net profit, net worth, debt and assets for every filing year, 15+ ratios, the financial health score, shareholding, charges and peer comparison are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Credit assessment · Manufacturing
Rating Methodology – Manufacturing Companies (Mar 2025) · Consolidated accounts · FY 2022-23
Indicative long-term—
Indicative short-term—
Score—
LiquidityStretched
DirectionStable
Ratios, pillar scores and the indicative rating are part of Premium.
Rating status
| Default | No default on record |
| Issuer cooperation | Cooperating |
| Credit enhancement | None – standalone rating |
| Information on file | 22% · missing: Audited financial statements (last 18 months), Debt obligations and repayment schedule, Capex / investment plans, Lender details, Auditor details, Shareholding pattern, Recent rating review (last 15 months) |
Indicative assessment from public data using the published methodology factors; not a credit rating.
Registered office and contact
Registered officeCambridge
GSTIN—
Email—
Websitehttp://www.alnylam.com
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Alnylam Pharmaceuticals
Competitors10identified
Countries1most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | lilly.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | jjmt.com.tw | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | pg.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | merck.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | amgen.com | 1983 | United States | |
| Part of Gilead Sciences. | gilead.com | 1992 | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | abbott.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | pfizer.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | bms.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | marriott.com.cn | — | United States |
Similar companies
M
Mirum PharmaceuticalsPharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing
S
Sight Sciences Inc.Pharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing
A
Arrowhead PharmaceuticalsPharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing
F
Femasys Inc.Pharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing
B
Beyond Air Inc.Pharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing
N
Nakamoto Inc.Pharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing
M
Mesa Laboratories Inc.Pharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing
H
Healthcare Realty Trust IncorporatedPharmaceuticals & Healthcare
Same segment: Formulations & Contract Manufacturing · Similar revenue scale
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
pharmaceutical industry
Filings
No filings on record yet.